CD19 and neoplasm: To enhance the tumor targeting of CAR T-cells, Priceman’s group designed an oncolytic VACV (OV19t) encoding a non-signaling, truncated human CD19 (CD19t) protein in which highly expressed CD19t on the surface of tumor cells worked as a specific tumor antigen to enable the tumor targeting of CD19-CAR T-cells (85).